Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Medical Research Council (NMRC), Singapore | OTHER_GOV |
| Duke-NUS Graduate Medical School | OTHER |
| Ferring Pharmaceuticals | INDUSTRY |
| ImmunoSCAPE |
Not provided
Not provided
Not provided
Not provided
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples | Whole exome sequencing, single nucleotide polymorphism (SNP) assays | Blood is taken at informed consent; tissue is from archived sample |
| Change in immune profile of blood and tissue after radiation | Mass cytometry using CyTOF technology will be used to detect the immune cell population | Blood is taken at informed consent; tissue is from archived sample |
| To identify proteins that are associated with radiation sensitivity in tissue samples | Immunohistochemistry will be used to detect protein expression | Tissue is from archived sample |
| To identify RNA expression pathways that are associated with radiation sensitivity in blood and tissue samples | RNA sequencing | Blood is taken at informed consent; tissue is from archived sample |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Participants will be recruited from patients of the study team when they attend their regular clinic visits or when they are admitted to the hospital. These are patients from NCCS.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Melvin Chua, MD | Contact | melvin.chua.l.k@singhealth.com.sg | ||
| Enya Ong | Contact | +65 6436 8000 | enya.ong.h.w@nccs.com.sg |
| Name | Affiliation | Role |
|---|---|---|
| Melvin Chua, MD | National Cancer Centre, Singapore | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Cancer Center Singapore | Recruiting | Singapore | 169690 | Singapore |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009303 | Nasopharyngeal Neoplasms |
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D010610 | Pharyngeal Neoplasms |
| D010039 | Otorhinolaryngologic Neoplasms |
| D006258 | Head and Neck Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| INDUSTRY |
| Decipher Biosciences | UNKNOWN |
Not provided
Not provided
Not provided
20mL of blood will be collected up to 5 times over 5 years
| D009369 | Neoplasms |
| D009302 | Nasopharyngeal Diseases |
| D010608 | Pharyngeal Diseases |
| D009057 | Stomatognathic Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |